Hovione and H&T Presspart have entered into a strategic partnership to advance the development of Presspart's Sunriser Capsule-based Dry Powder Inhaler platform.
The demand for inhalable drugs that require higher drug loads and the delivery of cohesive materials has increased, making it necessary to develop more efficient solutions. To meet this demand, the two companies will work together to develop the Sunriser Dry Powder Inhaler. This innovative and best-in-class capsule-based platform is flexible enough to address both the challenges of classic carrier-based and spray-dried engineered formulations.
This partnership is an extension of a successful collaboration that has spanned several years on developing and commercialising innovative dry powder inhalation devices. As part of the joint development agreement, Hovione will exclusively partner with Presspart to exploit the Sunriser device in the field of engineered formulations for dry powder inhalation.
Presspart will remain responsible for the manufacturing of the Sunriser device. To provide further insights into the benefits of this partnership for the industry, a joint workshop will be held on May 3, at the Respiratory Drug Delivery (RDD) Europe 2023.
"New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung,” said Dr Jean-Luc Herbeaux, Hovione’s CEO. He added: “We are thrilled to expand our current partnership with Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients.”
As the market leader in respiratory components and devices, this strategic partnership will allow H&T Presspart to expand its portfolio
Christian Kraetzig, President of H&T Presspart, commented: “Following our successful collaboration with Hovione on the PowdAir Plus DPI device development, we are once again extremely pleased to be working with Hovione in developing this next generation high performance DPI device. As the market leader in respiratory components and devices, this strategic partnership will allow H&T Presspart to expand its portfolio within the growing field of dry powder technology.”
Pharmaceutical companies partnering with Hovione to develop their new inhalable drugs using the Sunriser device can leverage Hovione´s unparalleled expertise in inhalable APIs, formulation, filling, and analytical characterisation.
Additionally, with H&T Presspart's state-of-the-art device manufacturing and supply, from lab to commercial cGMP scale, companies can benefit from a comprehensive approach to drug development. This partnership enables pharmaceutical companies to access top-notch expertise and cutting-edge technology, ensuring the successful development and commercialisation of innovative inhalable drugs.
